In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed concern about the agency’s proposal to retrospectively effectuate the policy.

The AHA called CMS’ retrospective refund process “complex, burdensome and would be operationally unworkable,” and could unwillingly cause providers to pursue rebates and 340B discounts from drug manufacturers instead of requiring them to make lower negotiated prices available upfront. The AHA urged CMS to finalize a prospective process that aligns with the Health Resources and Services Administration’s historic interpretation of the 340B statutory requirements and balances the interests of Medicare patients, dispensing entities and manufacturers under the program.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…